Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies

N. D. Prins,W. de Haan,A. Gardner,K. Blackburn,H.-M. Chu,J. E. Galvin,John J. Alam,N.D. Prins,J.E. Galvin,J.J. Alam

DOI: https://doi.org/10.14283/jpad.2024.36

2024-01-01

Abstract:BackgroundIn an exploratory 91-participant phase 2a clinical trial (AscenD-LB, NCT04001517) in dementia with Lewy bodies (DLB), neflamapimod showed improvement over placebo on multiple clinical endpoints. To confirm those results, a phase 2b clinical study (RewinD-LB, NCT05869669 ) that is similar to AscenD-LB has been initiated.ObjectivesTo optimize the choice of patient population, primary endpoint, and biomarker evaluations in RewinD-LB.DesignEvaluation of the efficacy results from AscenD-LB, the main results of which, and a re-analysis after stratification for absence or presence of AD co-pathology (assessed by plasma ptau181), have been published. In addition, the MRI data from a prior phase 2a clinical trial in Early Alzheimer’s disease (AD), were reviewed.Setting22 clinical sites in the US and 2 in the Netherlands.ParticipantsProbable DLB by consensus criteria and abnormal dopamine uptake by DaTscan™ (Ioflupane I123 SPECT).InterventionNeflamapimod 40mg capsules or matching placebo capsules, twice-a-day (BID) or three-times-a-day (TID), for 16 weeks.Measurements6-test Neuropsychological Test Battery (NTB) assessing attention and executive function, Clinical Dementia Rating Sum-of-Boxes (CDR-SB), Timed Up and Go (TUG), International Shopping List Test (ISLT).ResultsWithin AscenD-LB, patients without evidence of AD co-pathology exhibited a neflamapimod treatment effect that was greater than that in the overall population and substantial (cohen’s d effect size vs. placebo ≥ for CDR-SB, TUG, Attention and ISLT-recognition). In addition, the CDR-SB and TUG performed better than the cognitive tests to demonstrate neflamapimod treatment effect in comparison to placebo. Further, clinical trial simulations indicate with 160-patients (randomized 1:1), RewinD-LB conducted in patients without AD co-pathology has >95% (approaching 100%) statistical power to detect significant improvement over placebo on the CDR-SB. Preliminary evidence of positive treatment effects on beta functional connectivity by EEG and basal forebrain atrophy by MRI were obtained in AscenD-LB and the Early AD study, respectively.ConclusionIn addition to use of a single dose regimen of neflamapimod (40mg TID), key distinctions between phase 2b and phase 2a include RewinD-LB (1) excluding patients with AD co-pathology, (2) having CDR-SB as the primary endpoint, and (3) having MRI studies to evaluate effects on basal forebrain atrophy.

clinical neurology

What problem does this paper attempt to address?

The paper aims to address the following issues:

1. **Optimizing Patient Population Selection**: By analyzing the results of the previous AscenD-LB trial, identify patients with comorbid Alzheimer's disease (AD) pathology to be excluded in the RewinD-LB trial to enhance the ability to detect the drug's efficacy.

2. **Selecting Primary Clinical Endpoint**: Based on the results of the AscenD-LB trial, choose the Clinical Dementia Rating Sum-of-Boxes (CDR-SB) as the primary clinical endpoint, as it better demonstrates the drug's effect compared to cognitive tests.

3. **Biomarker Assessment**: Include magnetic resonance imaging (MRI) to assess basal forebrain atrophy in the RewinD-LB trial as a potential biomarker to evaluate the drug's effect.

The paper details the results of the AscenD-LB trial and analyzes the performance of different doses, patient groups, and various clinical tests. Through these analyses, researchers concluded that the effect of neflamapimod is more significant after excluding patients with AD comorbid pathology. Additionally, CDR-SB and Timed Up and Go (TUG) tests better demonstrate the drug's therapeutic effect compared to other cognitive tests. Therefore, the design of the RewinD-LB trial will focus on these aspects to improve statistical power and further validate the potential efficacy of neflamapimod in patients with dementia with Lewy bodies (DLB).